A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
Clinical trial NCT05921903 · COMPLETED
Trial details
- NCT number
- NCT05921903
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-28
- Primary completion
- 2024-06-25
- Enrollment
- 386
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.